The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Open accessAbstract
For most patients with chronic myeloid leukemia, tyrosine kinase inhibitors (TKIs) have turned a fatal disease into a manageable chronic condition. Imatinib, the first BCR-ABL1 TKI granted regulatory approval, has been surpassed in terms of molecular responses by the second-generation TKIs nilotinib, dasatinib, and bosutinib. Recently, ponatinib was approved as the only TKI with activity against the T315I mutation. Although all TKIs are associated with nonhematologic adverse events (AEs), experience with imatinib suggested that toxicities are typically manageable and apparent early during drug development. Recent reports of cardiovascular AEs with nilotinib and particularly ponatinib and of pulmonary arterial hypertension with dasatinib have raised concerns about long-term sequelae of drugs that may be administered for decades. Here, we review what is currently known about the cardiovascular toxicities of BCR-ABL1 TKIs, discuss potential mechanisms underlying cardiovascular AEs, and elucidate discrepancies between the reporting of such AEs between oncology and cardiovascular trials. Whenever possible, we provide practical recommendations, but we concede that cause-directed interventions will require better mechanistic understanding. We suggest that chronic myeloid leukemia heralds a fundamental shift in oncology toward effective but mostly noncurative long-term therapies. Realizing the full potential of these treatments will require a proactive rational approach to minimize long-term cardiovascular and cardiometabolic toxicities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka, L. F., Murphy, W. R. C., Olin, J. W., Puschett, J. B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174526 · Cited by 3,708
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationTargeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Mahon, F.-X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,550
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
van Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
O'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
Self-citationCardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Self-citationHeinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Reversal of experimental pulmonary hypertension by PDGF inhibition
Schermuly, R. T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24838 · Cited by 1,058
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka, L. F., Murphy, W. R. C., Olin, J. W., Puschett, J. B., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.009 · Cited by 1,021
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769
Self-citationRoss, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Yeung, D. T., Dang, P., Goyne, J. M., Slader, C., Filshie, R. J., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483750 · Cited by 710
Rix, U., Hantschel, O., Dürnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., et al. (2007) · Blood · doi:10.1182/blood-2007-07-102061 · Cited by 671
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
Montani, D., Bergot, E., Günther, S., Savale, L., Bergeron, A., Bourdin, A., Bouvaist, H., Canuet, M., Pison, C., Macro, M., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.079921 · Cited by 659
Kantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., Wang, J., Kassack Ipiña, J. J., Kim, D.-W., Ogura, M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-376087 · Cited by 610
Hoeper, M. M., Barst, R. J., Bourge, R. C., Feldman, J., Frost, A. E., Galié, N., Gómez-Sánchez, M. A., Grimminger, F., Grünig, E., Hassoun, P. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000765 · Cited by 574
O'Brien, S., Furman, R. R., Coutre, S. E., Sharman, J. P., Burger, J. A., Blum, K. A., Grant, B., Richards, D. A., Coleman, M., Wierda, W. G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70513-8 · Cited by 466
Cortes, J. E., Kim, D.-W., Kantarjian, H. M., Brümmendorf, T. H., Dyagil, I., Griskevicius, L., Malhotra, H., Powell, C., Gogat, K., Countouriotis, A. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7522 · Cited by 466
Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa065959 · Cited by 442
Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D.-W., Flinn, I. W., Kurokawa, M., Moiraghi, B., Yu, R., et al. (2012) · Leukemia · doi:10.1038/leu.2012.134 · Cited by 442
Gambacorti-Passerini, C., Antolini, L., Mahon, F.-X., Guilhot, F., Deininger, M., Fava, C., Nagler, A., Della Casa, C. M., Morra, E., Abruzzese, E., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr060 · Cited by 429
Self-citationJabbour, E., Kantarjian, H. M., Saglio, G., Steegmann, J. L., Shah, N. P., Boqué, C., Chuah, C., Pavlovsky, C., Mayer, J., Cortes, J., et al. (2014) · Blood · doi:10.1182/blood-2013-06-511592 · Cited by 395
Wu, S., Chen, J. J., Kudelka, A., Lu, J., & Zhu, X. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70003-2 · Cited by 386
Zhu, X., Stergiopoulos, K., & Wu, S. (2009) · Acta Oncologica · doi:10.1080/02841860802314720 · Cited by 312
Pushing the limits of targeted therapy in chronic myeloid leukaemia
O'Hare, T., Zabriskie, M. S., Eiring, A. M., & Deininger, M. W. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3317 · Cited by 304
Self-citationAichberger, K. J., Herndlhofer, S., Schernthaner, G., Schillinger, M., Mitterbauer‐Hohendanner, G., Sillaber, C., & Valent, P. (2011) · American Journal of Hematology · doi:10.1002/ajh.22037 · Cited by 296
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Valent, P., Hadzijusufovic, E., Schernthaner, G.-H., Wolf, D., Rea, D., & le Coutre, P. (2015) · Blood · doi:10.1182/blood-2014-09-594432 · Cited by 283
Congestive heart failure is a rare event in patients receiving imatinib therapy
Atallah, E., Durand, J.-B., Kantarjian, H., & Cortes, J. (2007) · Blood · doi:10.1182/blood-2007-01-070144 · Cited by 252
The regulatory crosstalk between kinases and proteases in cancer
López-Otín, C., & Hunter, T. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2823 · Cited by 244
Kim, T. D., Rea, D., Schwarz, M., Grille, P., Nicolini, F. E., Rosti, G., Levato, L., Giles, F. J., Dombret, H., Mirault, T., et al. (2013) · Leukemia · doi:10.1038/leu.2013.70 · Cited by 233
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice
Louvet, C., Szot, G. L., Lang, J., Lee, M. R., Martinier, N., Bollag, G., Zhu, S., Weiss, A., & Bluestone, J. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810246105 · Cited by 217
Giles, F. J., Mauro, M. J., Hong, F., Ortmann, C.-E., McNeill, C., Woodman, R. C., Hochhaus, A., le Coutre, P. D., & Saglio, G. (2013) · Leukemia · doi:10.1038/leu.2013.69 · Cited by 216
Brümmendorf, T. H., Cortes, J. E., de Souza, C. A., Guilhot, F., Duvillié, L., Pavlov, D., Gogat, K., Countouriotis, A. M., & Gambacorti‐Passerini, C. (2015) · British Journal of Haematology · doi:10.1111/bjh.13108 · Cited by 194
Dorer, D. J., Knickerbocker, R. K., Baccarani, M., Cortes, J. E., Hochhaus, A., Talpaz, M., & Haluska, F. G. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.07.007 · Cited by 166
Faxon, D. P., Creager, M. A., Smith, S. C., Pasternak, R. C., Olin, J. W., Bettmann, M. A., Criqui, M. H., Milani, R. V., Loscalzo, J., Kaufman, J. A., et al. (2004) · Circulation · doi:10.1161/01.cir.0000128517.52533.db · Cited by 159
Severe Peripheral Arterial Disease During Nilotinib Therapy
Le Coutre, P., Rea, D., Abruzzese, E., Dombret, H., Trawinska, M. M., Herndlhofer, S., Dorken, B., & Valent, P. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr292 · Cited by 159
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic
Fernández, A., Sanguino, A., Peng, Z., Ozturk, E., Chen, J., Crespo, A., Wulf, S., Shavrin, A., Qin, C., Ma, J., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32373 · Cited by 158
The global pandemic of peripheral artery disease
Hirsch, A. T., & Duval, S. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61576-7 · Cited by 151
Réa, D., Mirault, T., Cluzeau, T., Gautier, J., Guilhot, F., Dombret, H., & Messas, E. (2014) · Haematologica · doi:10.3324/haematol.2014.104075 · Cited by 150
Imatinib Attenuates Diabetes-Associated Atherosclerosis
Lassila, M., Allen, T. J., Cao, Z., Thallas, V., Jandeleit-Dahm, K. A. M., Candido, R., & Cooper, M. E. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000124105.39900.db · Cited by 148
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
Takahashi, N., Kyo, T., Maeda, Y., Sugihara, T., Usuki, K., Kawaguchi, T., Usui, N., Okamoto, S., Ohe, Y., Ohtake, S., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.056853 · Cited by 147
Imatinib and Regression of Type 2 Diabetes
Veneri, D., Franchini, M., & Bonora, E. (2005) · New England Journal of Medicine · doi:10.1056/nejm200503103521023 · Cited by 132
Bair, S. M., Choueiri, T. K., & Moslehi, J. J. (2013) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2012.09.008 · Cited by 119
Self-citationClinical cardiac safety profile of nilotinib
Kim, T. D., le Coutre, P., Schwarz, M., Grille, P., Levitin, M., Fateh‐Moghadam, S., Giles, F. J., Dörken, B., Haverkamp, W., & Köhncke, C. (2012) · Haematologica · doi:10.3324/haematol.2011.058776 · Cited by 118
Uitdehaag, J. C. M., de Roos, J. A. D. M., van Doornmalen, A. M., Prinsen, M. B. W., de Man, J., Tanizawa, Y., Kawase, Y., Yoshino, K., Buijsman, R. C., & Zaman, G. J. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092146 · Cited by 116
Breccia, M., Muscaritoli, M., Aversa, Z., Mandelli, F., & Alimena, G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.217 · Cited by 106
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Hatfield, A. K., Owen, S., & Pilot, P. R. (2007) · Nature Medicine · doi:10.1038/nm0107-13a · Cited by 100
Cancer-Drug Discovery and Cardiovascular Surveillance
Groarke, J. D., Cheng, S., & Moslehi, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1313140 · Cited by 83
Self-citationLoren, C. P., Aslan, J. E., Rigg, R. A., Nowak, M. S., Healy, L. D., Gruber, A., Druker, B. J., & McCarty, O. J. T. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.009 · Cited by 80
Trent, J. C., Patel, S. S., Zhang, J., Araujo, D. M., Plana, J., Lenihan, D. J., Fan, D., PATEL, S. R., Benjamin, R. S., & Khakoo, A. Y. (2009) · Cancer · doi:10.1002/cncr.24683 · Cited by 77
Levato, L., Cantaffa, R., Kropp, M. G., Magro, D., Piro, E., & Molica, S. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12096 · Cited by 75
Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies
Wolf, A., Couttet, P., Dong, M., Grenet, O., Heron, M. I., Junker, U., Laengle, U. W., Ledieu, D., Marrer, E., Nussher, A., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.01.004 · Cited by 70
Hsu, S., Ton, V., Ashen, M. D., Martin, S. S., Gluckman, T. J., Kohli, P., Sisson, S. D., Blumenthal, R. S., & Blaha, M. J. (2013) · Clinical Cardiology · doi:10.1002/clc.22137 · Cited by 69
The Cardiovascular Perils of Cancer Survivorship
Moslehi, J. J. (2013) · New England Journal of Medicine · doi:10.1056/nejme1215300 · Cited by 69
Self-citationShah, A. M., Campbell, P., Rocha, G. Q., Peacock, A. J., Barst, R. J., Quinn, D. A., Solomon, S. D., & for the IMPRES Investigators (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu035 · Cited by 65
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Rosti, G., Martinelli, G., & Baccarani, M. (2007) · Nature Medicine · doi:10.1038/nm0107-15a · Cited by 59
Raisi‐Estabragh, Z., Knight, K., Watmough, S. J., Lane, S., Vinjamuri, S., Hart, G., & Clark, R. E. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.08.020 · Cited by 53
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Atallah, E. L., Kantarjian, H. M., & Cortes, J. E. (2007) · Nature Medicine · doi:10.1038/nm0107-14 · Cited by 49
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Gambacorti, C., Tornaghi, L., Franceschino, A., Piazza, R., Corneo, G. M., & Pogliani, E. (2007) · Nature Medicine · doi:10.1038/nm0107-13b · Cited by 48
Knickerbocker, R. K., Dorer, D. J., Haluska, F. G., Baccarani, M., Cortes, J. E., Hochhaus, A., & Talpaz, M. (2014) · Blood · doi:10.1182/blood.v124.21.4546.4546 · Cited by 46
Ibrutinib in relapsed chronic lymphocytic leukemia.
Byrd, J. C., O'Brien, S. M., & James, D. F. (2013) · PubMed · doi:10.1056/nejmc1309710 · Cited by 42
Breccia, M., Loglisci, G., Salaroli, A., Serrao, A., & Alimena, G. (2012) · Leukemia Research · doi:10.1016/j.leukres.2011.12.011 · Cited by 29
Huber, T. S. (2008) · Perspectives in Vascular Surgery · doi:10.1177/1531003508319779 · Cited by 23
Mariani, S., Tornaghi, L., Sassone, M. C., Basciani, S., Buzzetti, R., Gambacorti-Passerini, C. B., Spera, G., & Gnessi, L. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.08.003 · Cited by 16
Chamrád, I., Rix, U., Stukalov, A., Gridling, M., Parapatics, K., Müller, A. C., Altiok, S., Colinge, J., Superti‐Furga, G., Haura, E. B., et al. (2013) · Journal of Proteome Research · doi:10.1021/pr400309p · Cited by 15
Deininger, M. W., & Manley, P. W. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.09.018 · Cited by 15
Self-citationGoodrich, A. D. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.958465 · Cited by 9
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Metadata
- Authors
- Moslehi, J. J., & Deininger, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-12-10
- Volume
- 33
- Issue
- 35
- Pages
- 4210-4218
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1939978733
- Cited by
- 443
- References
- 75
- FWCI
- 28.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.